A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers

Trial Profile

A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Veliparib (Primary) ; Floxuridine
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 28 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 19 Jan 2018 Planned primary completion date changed from 30 Jun 2017 to 16 Jan 2019.
    • 17 Oct 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top